IMPAKT 2014: Sponsors

Gold Sponsor

Roche

1 Grenzacherstrasse 124
Basel, 4070
Switzerland
Tel: +41 61 688 11 11
Fax: +41 61 691 93 91

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-four medicines developed by Roche are included in the WHO Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy. In 2013 the Roche Group employed over 85,000 people worldwide, invested 8.7 billion Swiss francs in R&D and posted sales of 46.8 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

Silver Sponsor

Pfizer Oncology

1 235 E. 42nd Street
New York, NY 10017
United States of America
Tel: + 212-733-2323

Pfizer Oncology is committed to the discovery, investigation and development of innovative treatment options to improve the outlook for cancer patients worldwide. Our strong pipeline of biologics and small molecules is studied with precise focus on identifying and translating the best scientific breakthroughs into clinical application for patients across a wide range of cancers.

Bronze Sponsors

Genomic Health International Sàrl

Quai du Seujet 10
1201 Geneva
Switzerland
Tel: +41 22 715 29 00
Fax: +41 44 583 07 87
E-mail: europeansupport@genomichealth.com

Genomic Health is the world’s leading provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of early stage cancer, one of the greatest issues in healthcare today. The company is applying its world-class scientific and commercial expertise and infrastructure to lead the translation of massive amounts of genomic data into clinically-actionable results for treatment planning throughout the cancer patient’s journey, from screening and surveillance, through diagnosis, treatment selection and monitoring. The company is based in Redwood City, California with European headquarters in Geneva, Switzerland.

NanoString Technologies Europe Limited

11th Floor Whitefriars
Lewins Mead
Bristol BS1 2NT
United Kingdom
Tel: +44 (0) 7538 301168
E-mail: cmcdonnell@nanostring.com

NanoString Technologies provides innovative products that unlock valuable and clinically actionable genomic information from small amounts of tissue. The company is committed to offering tools that enable scientists and clinicians to translate today’s leading genomic research into clinically actionable tests that improve patient care. 

Participating Sponsor

AbbVie

1 North Waukegan Road
North Chicago, IL 60064
United States of America
Tel: +1-800-255-5162

AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world’s most complex and serious diseases. In 2014, AbbVie employs approximately 21,000 people worldwide and markets medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, please visit www.abbvie.com. Follow @abbvie on Twitter.

Breakthrough Breast Cancer

Weston House
246 High Holborn
London, WC1V 7EX
United Kingdom
Tel: +44 20 7025 2400
Fax: +44 20 7025 2401
E-mail: info@breakthrough.org.uk

Breakthrough Breast Cancer's mission is to save lives through improvements in breast cancer, prevention, diagnosis and treatment.

Under the overarching goal of a personalised approach to medicine, the strategy is defined by four priority areas:

  • By finding the causes we will know how to prevent the disease.
  • By promoting early detection more women will recognise the signs and symptoms of breast cancer.
  • By finding ways to make diagnosis of the disease more accurate, more women will receive precise treatments.
  • By discovering new and better treatments and improving health services, women will receive effective guaranteed treatments and care.

MYRIAD GENETICS GmbH

Myriad Logo

Leutschenbachstrasse 95
8050 Zurich
Switzerland
Tel: +41 44 939 91 44
Fax: +41 44 939 91 31
E-mail: info@myriadgenetics.eu

Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patient’s lives through the discovery and commercialization of transformative tests to assess a person’s risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence.

Premium Educational Grant

Celgene International

Route de Perreux 1
2017 Boudry
Switzerland
Tel: +41 32 729 85 00
Fax:+41 32 729 85 08
E-mail: medinfo@celgene.com 

Celgene is a global biopharmaceutical company committed to improving the lives of patients worldwide. We seek to deliver truly innovative and life-changing drugs for our patients through the discovery, development, and commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions. We believe all who can benefit from our discoveries should have the opportunity to do so. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies. Celgene employs more than 4500 employees worldwide.

Standard Educational Grant Sponsor

Eisai SA

Square de Meeus 38/40
Office no. 406
B–1000 Bruxelles
Belgium
Tel: +32 (0)2 502 58 04
Fax: +31 20 575 3341

Eisai: Manufacturing and marketing of pharmaceutical drugs, over-the-counter drugs and Pharmaceuticals Production Systems. Eisai is committed to making contributions to better healthcare for patients and their families around the world through its business activities. Halaven® (eribulin): Synthetic derivative of halichondrin B, a natural marine product derived from the sea sponge Halichondria okadai. It is a new anticancer treatment that acts against tumors by suppressing the growth of microtubules by blocking the polymerization of tubulin, a structural component of microtubules, thereby impeding cellular mitosis. Currently approved in 52 countries and territories, marketed under the brand name Halaven® in the United States, Europe, Singapore and Japan.